Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3D hypoxia-preconditioned umbilical cord-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
3D hypoxia-preconditioned umbilical cord-derived mesenchymal stem cells (UC-MSCs) are an advanced cell therapy product developed by the Chinese PLA General Hospital. Unlike traditional 2D-cultured MSCs, these cells are grown in a three-dimensional environment and subjected to low-oxygen (hypoxic) conditions during expansion. This specialized manufacturing process is intended to enhance the cells' therapeutic potency, survival, and secretion of immunomodulatory and hematopoietic growth factors by mimicking the natural physiological conditions of the bone marrow niche. The therapy is primarily being investigated as a sequential infusion in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for severe aplastic anemia, with the aim of improving donor cell engraftment rates and reducing the risk of graft-versus-host disease (GVHD).
- Other names
- Hypoxic 3D-cultured umbilical cord mesenchymal stem cellsHypoxic3D-cultured umbilical cord mesenchymal stem cellsHypoxic-3D-cultured umbilical cord mesenchymal stem cells3D hypoxia-preconditioned UC-MSCs3D-hUC-MSCs
Beyond the preview
Go deeper on 3D hypoxia-preconditioned umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3D hypoxia-preconditioned umbilical cord-derived mesenchymal stem cells.